|
|
Display all categories
|
|
Most Recent VideoCasts
|
|
NCI CCR Grand Rounds (NIH Only) |
| | | | Chemokine Receptors in Organ-Selective Cancer Metastasis (NIH-Only)
Tuesday, May 24, 2005
Sam T. Hwang, M.D., Ph.D., Center for Cancer Research, NCI
Total Running Time: 01:04:33 more information | |
| Checkpoint Inhibition: A New Strategy for Tumor Immunotherapy (NIH-Only)
Tuesday, May 10, 2005
James P. Allison, Ph.D., Memorial Sloan-Kettering Cancer Center
Total Running Time: 00:59:17 more information | |
| Chronic Inflammation and Cancer: Radical Causes of Cancer (NIH-Only)
Tuesday, May 03, 2005
Curtis C. Harris, M.D., Center for Cancer Research, NCI
Total Running Time: 01:04:08 more information | |
| Recent Advances in Prophylactic HPV Cervical Cancer Vaccines (NIH-Only)
Tuesday, April 26, 2005
John T. Schiller, Ph.D., Center for Cancer Research, NCI
Total Running Time: 01:00:07 more information | |
| Impact of EGFR Mutations on the Treatment of Lung Cancer (NIH-Only)
Tuesday, April 12, 2005
Bruce E. Johnson, M.D., Harvard Medical School
Total Running Time: 01:01:30 more information | |
| RhoGDI2 - New Metastasis Suppressor in Bladder Cancer (NIH-Only)
Tuesday, April 05, 2005
Dan Theodorescu, MD, PhD, University of Virginia
Total Running Time: 01:08:53 more information | |
| Toward the Last Cohort (NIH-Only)
Tuesday, March 29, 2005
John Potter, M.D., Ph.D., Fred Hutchinson Cancer Research Center
Total Running Time: 01:03:26 more information | |
| Targeting the Myeloma Cell in its Microenvironment (NIH-Only)
Tuesday, March 22, 2005
Kenneth C. Anderson, M.D., Dana-Farber Cancer Institute
Total Running Time: 01:16:49 more information | |
| Roadside to Bedside: Natural Products Providing Path to Therapeutic Targets (NIH-Only)
Tuesday, March 08, 2005
Peter M. Blumberg, Ph.D., NCI
Total Running Time: 01:08:56 more information | |
| Keratinocyte Growth Factor: from Basic Research to Clinical Application (NIH-Only)
Tuesday, March 01, 2005
Jeffrey S. Rubin, M.D., Ph.D., NCI
Total Running Time: 01:01:41 more information | |
|
| |
|
Comments: VideoCast Issues, technical and content questions
|
|